We have located links that may give you full text access.
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
The iScore predicts efficacy and risk of bleeding in the National Institute of Neurological disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association 2013 August
The iScore is a validated tool to estimate outcomes after an acute ischemic stroke. A previous study showed the iScore can predict clinical response and risk of intracerebral hemorrhage (ICH) after administration of tissue plasminogen activator (tPA). We applied the iScore (www.sorcan.ca/iscore) to participants in the National Institute of Neurological Disorders and Stroke tPA stroke trials to evaluate its ability to estimate clinical response and risk of ICH after thrombolysis. Based on results from our previous study, patients were stratified a priori into iScore <200 and iScore ≥ 200. The main outcome measure was ICH. Secondary outcomes included favorable composite outcome (defined as a modified Rankin Scale score of 0 or 1, National Institutes of Health Stroke Scale score ≤ 1, Barthel Index ≥ 95, or Glasgow Outcome Scale <1 at 3 months) and functional outcomes. The iScore was calculated in all 624 patients enrolled in the trial. The cohort comprised 507 patients (81%) with an iScore <200 and 117 (19%) with an iScore ≥ 200. An iScore ≥ 200 was associated with greater risk of symptomatic ICH in the tPA group compared with the placebo group (15.4% v 3.9%; P = .04). Similar findings were found for ICH of any type (30.8% v 11.5%; P = .014), with higher ICH mortality (69.2% v 23.8%; P < .001). Despite the higher favorable composite outcome of tPA therapy in patients with an iScore <200 (58.7% v 41.9%; P < .001), this therapy had no benefit in patients with an iScore ≥ 200 (15.4% v 13.4%; P = .77). In patients receiving tPA in the National Institute of Neurological Disorders and Stroke trial, the iScore estimated the clinical response and risk of hemorrhagic complications. Further prospective studies are needed before a change in practice can be recommended.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app